DIAD

Calling all adults during National Teen Driver Safety Week: Drive like the kids are watching…because they are

Retrieved on: 
Tuesday, October 17, 2023

October 15-21 marks National Teen Driver Safety Week and October 19 is designated as Do Not Disturb While Driving Day.

Key Points: 
  • October 15-21 marks National Teen Driver Safety Week and October 19 is designated as Do Not Disturb While Driving Day.
  • In addition, young drivers aged 16 to 24 have the highest crash risk out of all age cohorts as they learn to drive.
  • So, National Teen Driver Safety Week is a great reminder for adults and teens that your choices on the road matter.
  • For more information about TIRF’s Graduated Driver Licensing (GDL) Framework Safety Center, visit: https://gdlframework.tirf.ca/module/components
    For more information about National Teen Driver Safety Week, visit: https://parachute.ca/NTDSW .

BioArctic's partner Eisai initiates BLA submission of data for lecanemab in China

Retrieved on: 
Friday, December 23, 2022

The registration category of lecanemab was designated as a Category 1 drug (innovative biologics not approved in China or any other countries).

Key Points: 
  • The registration category of lecanemab was designated as a Category 1 drug (innovative biologics not approved in China or any other countries).
  • Eisai will submit additional data including full data of the Clarity AD study, as directed by the NMPA.
  • In July 2022, the FDA accepted Eisai's Biologics License Application (BLA) for lecanemab under the accelerated approval pathway and granted it Priority Review.
  • Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

BioArctic's partner Eisai initiates BLA submission of data for lecanemab in China

Retrieved on: 
Friday, December 23, 2022

The registration category of lecanemab was designated as a Category 1 drug (innovative biologics not approved in China or any other countries).

Key Points: 
  • The registration category of lecanemab was designated as a Category 1 drug (innovative biologics not approved in China or any other countries).
  • Eisai will submit additional data including full data of the Clarity AD study, as directed by the NMPA.
  • In July 2022, the FDA accepted Eisai's Biologics License Application (BLA) for lecanemab under the accelerated approval pathway and granted it Priority Review.
  • Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

Eisai and Washington University School of Medicine in St. Louis Enter Into Comprehensive Research Collaboration Agreement Aiming to Create New Therapies for Neurodegenerative Diseases

Retrieved on: 
Thursday, December 15, 2022

TOKYO, Dec 15, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai and Washington University School of Medicine in St. Louis have entered into a comprehensive research collaboration agreement aiming to create potential novel treatments for neurodegenerative disorders, including Alzheimer's disease (AD) and Parkinson's disease (PD).

Key Points: 
  • TOKYO, Dec 15, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that Eisai and Washington University School of Medicine in St. Louis have entered into a comprehensive research collaboration agreement aiming to create potential novel treatments for neurodegenerative disorders, including Alzheimer's disease (AD) and Parkinson's disease (PD).
  • Washington University is world leading in research on prevention, diagnosis, biomarkers and treatment of neurodegenerative diseases.
  • The collaboration strategically combines Washington University scientists" expertise in the fundamental and clinical research in neurodegenerative diseases, such as dementia, with Eisai's extensive experience in drug discovery and development.
  • WashU Medicine is a global leader in academic medicine, including biomedical research, patient care and educational programs with 2,700 faculty.

EISAI AND WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS ENTER INTO COMPREHENSIVE RESEARCH COLLABORATION AGREEMENT AIMING TO CREATE NEW THERAPIES FOR NEURODEGENERATIVE DISEASES

Retrieved on: 
Wednesday, December 14, 2022

TOKYO, Dec. 14, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that Eisai and Washington University School of Medicine in St. Louis have entered into a comprehensive research collaboration agreement aiming to create potential novel treatments for neurodegenerative disorders, including Alzheimer's disease (AD) and Parkinson's disease (PD).

Key Points: 
  • TOKYO, Dec. 14, 2022 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that Eisai and Washington University School of Medicine in St. Louis have entered into a comprehensive research collaboration agreement aiming to create potential novel treatments for neurodegenerative disorders, including Alzheimer's disease (AD) and Parkinson's disease (PD).
  • Washington University is world leading in research on prevention, diagnosis, biomarkers and treatment of neurodegenerative diseases.
  • The collaboration strategically combines Washington University scientists' expertise in the fundamental and clinical research in neurodegenerative diseases, such as dementia, with Eisai's extensive experience in drug discovery and development.
  • In the case that Eisai chooses to exercise the options, Eisai will pay Washington University milestone payments and royalties on future sales of each licensed compounds.

Edward Jones Announces Significant Progress Toward Its $50 Million Commitment To Help Find a Cure for Alzheimer's

Retrieved on: 
Tuesday, December 6, 2022

ST. LOUIS, Dec. 6, 2022 /PRNewswire/ -- Financial services firm Edward Jones today announced it has raised more than $35 million toward its $50 million goal by the end of 2025 to support the Alzheimer's Association in the fight against Alzheimer's disease. In its Centennial year, the firm supported 624 walks, and since 2016 has recruited nearly 100,000 participants in the Walk to End Alzheimer's.

Key Points: 
  • In its Centennial year, the firm supported 624 walks, and since 2016 has recruited nearly 100,000 participants in the Walk to End Alzheimer's.
  • "The support of Edward Jones and the Alzheimer's Association has been a shining light for us during this time.
  • Edward Jones'contributions make it possible for those affected by the disease to reach trained Alzheimer's Association professionals on a dedicated Alzheimer's 24/7 Helpline (1-844-440-6600), supported by Edward Jones.
  • Edward Jones is a leading financial services firm in the U.S. and through its affiliate in Canada.

Eisai's Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study

Retrieved on: 
Wednesday, January 19, 2022

The study will assess the effect of Eisai's investigational anti-microtubule binding region (MTBR) tau antibody E2814, in dominantly inherited Alzheimer's disease (DIAD).

Key Points: 
  • The study will assess the effect of Eisai's investigational anti-microtubule binding region (MTBR) tau antibody E2814, in dominantly inherited Alzheimer's disease (DIAD).
  • In March 2021, the DIAN-TU selected E2814, which was created from a research collaboration between Eisai and University College London, as the first investigational medicine among anti-tau drugs for the Tau NexGen study.
  • With increasing evidence from clinical studies showing that targeting amyloid can reduce biomarkers of AD, the Tau NexGen clinical trial leaders selected Eisai's investigational anti-Abeta protofibril antibody lecanemab (BAN2401) as the background anti-amyloid therapy, and the study design was amended in November 2021.
  • In the Tau NexGen study, symptomatic participants will be administered anti-amyloid beta (Abeta) protofibril antibody lecanemab for six months before being randomly assigned to also receive the anti-tau drug or a placebo.

Eisai: DIAN-TU Selects Lecanemab as Background Anti-Amyloid Therapy in Clinical Trial Evaluating Investigational Therapy Targeting Tau for Dominantly Inherited Alzheimer's Disease

Retrieved on: 
Tuesday, November 9, 2021

The Tau NexGen clinical study was originally designed to focus on therapies that target tau.

Key Points: 
  • The Tau NexGen clinical study was originally designed to focus on therapies that target tau.
  • With increasing evidence from clinical studies showing that targeting amyloid can reduce biomarkers of Alzheimer's disease (AD), the Tau NexGen clinical trial leaders selected Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab as the background anti-amyloid agent.
  • "Eisai's anti-MTBR tau antibody E2814 was chosen as the first investigational therapy among anti-tau drugs for the groundbreaking Dominantly Inherited Alzheimer Network Trials Unit Tau NexGen, which was originally designed to target tau proteins.
  • An investigational anti-microtubule binding region (MTBR) tau antibody, E2814 is being developed as a disease modifying agent for tauopathies including sporadic AD.